High-Risk Mantle Cell Lymphoma CAR-T Cell Therapy Trial
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a new type of immune cell therapy (CAR-T cells) for patients with high-risk mantle cell lymphoma who have already received initial chemotherapy. The goal is to see if this personalized cell treatment can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of mantle cell lymphoma (a type of blood cancer) with specific genetic markers
- High-risk disease based on tumor characteristics (such as certain genetic mutations, fast-growing cells, or aggressive appearance)
- Completed 2 cycles of standard chemotherapy or targeted drug treatment that included an anti-CD20 antibody
- Cancer response to treatment (complete or partial response, or stable disease) confirmed by PET/CT or CT scan
- Good overall health (able to care for yourself or with minimal assistance)
- Normal kidney, heart, liver, and blood cell function; no active infections like HIV or hepatitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
This trial tests a combination of two treatments: a CAR-T cell therapy (relmacabtagene autoleucel) and an immunotherapy drug (sintilimab) for people with certain types of B-cell lymphoma that have come back or stopped responding to other treatments. The goal is to see if this combination can help control the cancer.
This trial tests a new type of CAR-T cell therapy for people with certain B-cell cancers (leukemia or lymphoma) that have not responded to standard treatments. It aims to see if these specially engineered immune cells can attack and destroy the cancer.
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
This study tests a type of immunotherapy called CAR-T cells (modified immune cells) for people with untreated, high-risk mantle cell lymphoma. It aims to see if this therapy can help control the disease early on.
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
Hear when a new Mantle Cell Lymphoma (MCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.